Physiomics PLC Presentation and Q&A on Company's Final Results

TIDMPYC

Physiomics PLC

06 October 2020

6 October 2020

Physiomics plc

("Physiomics" or "the Company")

Presentation and Q&A on Company's Final Results for the year ended 30 June 2020

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, yesterday made a presentation regarding its final results for the year ended 30 June 2020, using the Investor Meet Company platform. The slide deck used in the presentation can be accessed on our website https://www.physiomics.co.uk/wp-content/uploads/2020/10/Physiomics-Update-30-Sept-2020-vfinalr.pdf and a recording of the presentation, together with the subsequent Q&A, can be viewed by registering or logging on to Investor Meet Company at:

https://www.investormeetcompany.com/physiomics-plc/register-investor .

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

[phone]

Hybridan LLP (Broker)

Claire Louise Noyce

[phone]

Strand Hanson Ltd (NOMAD)

Richard Tulloch & James Dance

[phone]

About Physiomics

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour(TM) technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 70 projects, involving over 30 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.

Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.

Physiomics senior management has academic and commercial expertise, including over 120 years collectively of working in oncology and/or computational biology and over 120 publications in peer reviewed journals that have attracted thousands of citations.

For more information please visit:

www.physiomics.co.uk

www.twitter.com/Physiomics

www.linkedin.com/company/physiomics-plc/

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAUNVBRRVURRRA

(END) Dow Jones Newswires

October 06, 2020 04:00 ET (08:00 GMT)